Advanced search
Publication Cover
International Journal of General Medicine Volume 4, 2011 - Issue
Submit an article Journal homepage
56
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Procoagulant inhibitory properties of paclitaxel poliglumex

John Nemunaitis1 Mary Crowley Cancer Research Centers, Dallas, TX, USA;2 Baylor Sammons Cancer Center, Dallas, TX, USA;3 Texas Oncology, Dallas, TX, USACorrespondence[email protected]
,
Neil Senzer1 Mary Crowley Cancer Research Centers, Dallas, TX, USA;2 Baylor Sammons Cancer Center, Dallas, TX, USA;3 Texas Oncology, Dallas, TX, USA
,
Barry Cooper2 Baylor Sammons Cancer Center, Dallas, TX, USA;3 Texas Oncology, Dallas, TX, USA
,
Michael Nemunaitis1 Mary Crowley Cancer Research Centers, Dallas, TX, USA
,
Cynthia Bedell1 Mary Crowley Cancer Research Centers, Dallas, TX, USA
,
Jack W Singer4 Cell Therapeutics, Inc., Seattle, WA, USA
&
Fred B Oldham4 Cell Therapeutics, Inc., Seattle, WA, USA
 show all
Pages 5-11 | Published online: 15 Dec 2010

References

  • MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res198646638763922946403
  • GreishKFangJInutsukaTMacromolecular therapeutics: Advantages and prospects with special emphasis on solid tumour targetingClin Pharmacokinet2003421089110514531722
  • ChipmanSDOldhamFBPezzoniGBiological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugateInt J Nanomedicine2006137538317722272
  • SingerJWBakerBde VriesPPoly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: Characterization, preclinical pharmacology, and preliminary clinical dataAdv Exp Med Biol2003519819912675210
  • MilasLMasonKAHunterNPoly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurabilityInt J Radiat Oncol Biol Phys20035570771212573758
  • SingerJWShafferSBakerBPaclitaxel poliglumex (XYOTAX; CT-2103): An intracellularly targeted taxaneAnticancer Drugs2005624325415711176
  • SingerJWPaclitaxel poliglumex (XYOTAX, CT-2103): A macromolecular taxaneJ Control Release200510912012616297482
  • LangerCJCT-2103. A novel macromolecular taxane with potential advantages compared with conventional taxanesClin Lung Cancer20046 Suppl 2S85S8815638965
  • BoddyAVPlummerERToddRA phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedulesClin Cancer Res2005117834784016278406
  • SabbatiniPAghajanianCDizonDPhase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinomaJ Clin Oncol2004224523453115542803
  • NemunaitisJCunninghamCSenzerNPhase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumorsCancer Invest20052367167616377585
  • AdlerBKUnfractionated heparin and other antithrombin mediated anticoagulantsClin Lab Sci20041711311715168893
  • BransonHESlaterLMAndersonMGProthrombin time after heparin removal. Application to monitoring simultaneous anticoagulation with heparin and coumarinsAm J Clin Pathol197971665667453082
  • BeutlerELichtmanMACollerBSWilliams Hematology5th edNew York NYMcGraw-Hill1995

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.